Iron overload in sickle cell anemia : A study of 94 patients

##plugins.themes.academic_pro.article.sidebar##

Published Jun 10, 2011
Download
pdf
Vol. 89 No. 6 (2011): Issue Jun 2011

##plugins.themes.academic_pro.article.main##

Raouf Hafsia
Fatma Belakhal
Naouel Ben Salah
Emna Gouider
Wijden El Borgi

Abstract

Background: Sickle cell disease is an autosomal, recessive hemoglobinopathy characterized by hemolytic anemia. Red blood cell transfusions are uncommon therapeutic mainstay in sickle cell disease and repeated transfusions can result in iron overload. The predicted risks of iron overload and organ failure increase with both the duration of disease requiring transfusion therapy and the number of transfusions.
Aim: To assess the state of iron overload in patients with sickle ce anemia according to their number of transfusions.
Methods: The medical records of 94 patients with sickle cell anemia (46 had homozygous sickle cell disease, 41 had sickle-ß thalassemia, 7 had compound heterozygous hemoglobin: 4 SC and 3 SOArab) were retrospectively reviewed for the following: clinical exam, serum ferritin level, liver function tests, abdominal ultrasound exam and heart Doppler.
Results: 61% of our patients are from the Northern- west of the country. The average age is 18.29 years (2 to 62 years) and the sexratio is 0.62. In addition to parental consanguinity which is found in 28.72% of the cases. The average level of ferritin is 660.35 ng/ml. 41.5% of the patients have a high status of ferritin witch ranged from 521.4 to 3360 ng/ml. There is not a significant difference of ferritin level according to age, sex and a phenotype of sickle cell anemia.
However, it is higher among the transfused patients with a same phenotype (p<0.05). We found a correlation between serum ferritin levels and the number of transfusions (r =+0.74). Splenectomy has a preventive role because it allowed stopping the transfusion in 65% of the cases. The evaluation of organ dysfunction has found a hepatomegaly in 29% of the cases, half of witch were have a high status of serumferritin (> 1000 ng/ml). Left ventricular hypertrophy associated to valvulopathy was classified in 10 % of the cases.
Conclusion: Iron overload in sickle cell anemia, though relying on transfusion, remains moderate. The repetitive assessment of serum ferritin level is considered as the best test though it does not evaluate an organic dysfunction. To evaluate them better, other tests are requiring: magnetic resonance imaging and Tc-Squid biosusceptometers.

Keywords:

Hemochromatosis, ferritin, sickle cell anemia, transfusion

##plugins.themes.academic_pro.article.details##

References

  1. Franklin H, Eptein E. Pathogenesis and treatment of sickle cell disease. N Eng J Med 1997; 337:792-99.
  2. Slah A. Hemoglobinopathies and other congenital haemolytic anemia. Indian J of Med Sci 2004; 58:490-93.
  3. Labie D, Elion J. Bases moléculaires et physiopathologiques des maladies de l'hémoglobine.Encyclopédie médicale de Chirurgie. Paris: Elsevier Hematology 2005: 13-000-S-10,15p.
  4. Stuart MJ, Nagel RL. Sickle cell disease. Lancet 2004; 364:1343-60.
  5. Bachir D. L'hémochromatose post-transfusionnelle : est-elle moins grave chez les drépanocytaires. Hématologie 2000; 6:54- 58.
  6. Mellouli F, El Borgi W, Kaabi H,et al. HFE gene mutations in Tunisian major beta-Thalassemia and iron overload Transfus. Clin Biol. 2006; 13: 353-7.
  7. Cadet E, Granaderme M, Capron D. Données récentes sur le métabolisme du fer : un état de transition. Rev Med Interne 2005; 26:315-24.
  8. Gaillard O. La ferritine. Immuno-analyse et biologie spécialisée 2003;18:23-24.
  9. Hepcidin, haemoglobin and ferritin levels in sickle cell anaemia. Eur J Haematol. 2005; 74:86-88.
  10. Rogers J, Durmowicz G, Kasschau K et al. A motif within the 5' non-coding regions of acute phase mRNA mediates control of ferritin translation by Il 1 and may contribute to the anemia of chronic desease. Blood 1991; 78:361a.
  11. Fung EB, Harmatz P, Milet M. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematology 2007; 82:255-65.
  12. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemia, with particular reference to iron metabolism. Acta Haematol 1987; 78:198-205.
  13. Davies S, Henthorn JS, Win A. Effect of blood transfusion on iron status in sickle cell anaemia. Clin Lab Haematol 1984; 6:17-22.
  14. Harmatz P, Butensky E, Quirolo K. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76-79.
  15. Vichinsky E, Butensky E, Fung E et al. Comparison of organ dysfunction in transfused patients with SCD or ß thalassemia. Am. J. of Hematol. 2005; 80:70-74
  16. Richard S, Billet H. Liver function tests in sickle cell disease. Clin Lab Haematol 2002; 24:21-27.
  17. Harmatz P, Butensky E, Quirolo K. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76-79.
  18. Karam LB, Disco D, Jackson SM et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. Pediatr Blood Cancer 2007; 24:520-25.
  19. Brittenham GM, Cohen AR, Mclaren CE. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81-5.